Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposome amphotericin B
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposome amphotericin B is a unilamellar (single-layer) liposomal formulation of the antifungal agent amphotericin B. It is designed for intravenous administration and consists of amphotericin B intercalated within a true single bilayer liposome composed of phospholipids and cholesterol. This formulation improves the drug’s safety profile by reducing nephrotoxicity compared to conventional formulations. Liposome amphotericin B acts by binding to ergosterol in fungal cell membranes, creating pores that lead to cell death. It is FDA-approved for empirical therapy in febrile neutropenic patients with presumed fungal infection; treatment of invasive infections caused by Aspergillus species, Candida species, and/or Cryptococcus species refractory to conventional therapy; cryptococcal meningitis in HIV-infected patients; and visceral leishmaniasis[2][3][4][5][9]. Off-label uses include coccidioidomycosis, histoplasmosis, mucormycosis, blastomycosis, talaromycosis[5][6]. The product was developed as an improved delivery system for systemic antifungal therapy.
- Brand names
- AmBisome
- Other names
- liposomal amphotericin BL-AmB
02
Targets
ErgosterolChitin
Beyond the preview
Go deeper on liposome amphotericin B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposome amphotericin B.